Skip to main content

AIDS Vaccine Barcelona 2013

As the largest and final conference dedicated exclusively to AIDS vaccines, AIDS Vaccine 2013 was a forum for 1,000 leading researchers to share and discuss the latest progress and trends. Together with its partners, IAVI presented data from clinical trials, research programs and impact modeling in more than 40 sessions – including a plenary panel, three satellite symposia and 30 oral abstract & poster presentations – and celebrated community partners in a photo exhibit and reception.

We look forward to October 2014’s inaugural Research for Prevention conference in Cape Town, which will be dedicated to a broad range of biomedical HIV prevention research, including vaccines, antiretroviral-based prevention and other related areas.
Scientific Progress, Advocacy and Tribute
The Development of an AIDS Vaccine Will Require Sustained Time, Talent and Resources
In his opening remarks, Anthony Fauci, Director of the U.S. National Institutes of Allergy & Infectious Diseases (NIAID), reiterated for the field and the world that the quest for an AIDS vaccine is a marathon, not a sprint. Four days later, IAVI Chief Scientific Officer Wayne Koff concluded: “We leave Barcelona highly energized to continue this marathon and bring a safe and effective AIDS vaccine to the people who need it most.”

Past efficacy trials have given us a better sense of what doesn’t work and what might. More attention is now focused on accelerating next-generation candidates: Their development will benefit from an increasing understanding of the evolution of HIV by geography and in the body, of the maturation of broadly neutralizing antibodies (bNABs) and of the structure of the HIV envelope protein to which antibodies must bind to prevent infection. Promising new approaches in monkeys, including those using new replicating vectors, may pave the way for T-cell immune responses that can help destroy HIV-infected cells.

The following is a list of conference events involving IAVI and its partners.

Satellite Sessions
AIDS Vaccine Research at the Crossroads: How to Adapt to a New Prevention Agenda
Co-Organizers: IAVI, Amsterdam Institute for Global Health and Development (AIGHD) and  AVAC: Global Advocacy for HIV Prevention

At the satellite symposium “AIDS Vaccine Research at the Crossroads: How to Adapt to a New Prevention Agenda,” sponsored by IAVI, AVAC and AIGHD, 200 attendees examined the direction of vaccine research against the backdrop of evolving standards for HIV care and a post-2015 global health agenda. The symposium featured presentations by:  

• Margie McGlynn, IAVI CEO and President, on the public health policy implications impacting AIDS vaccine R&D [download PDF];
•  Glenda Gray, Executive Director of the Perinatal HIV Research Unit at the University of the Witwatersrand, South Africa, on the value and impact of human efficacy trials for HIV vaccines; [download PDF];
• Catherine Hankins, Deputy Director, Science, at the Amsterdam Institute for Global Health and Development (AIGHD) on the past, present and future HIV prevention research landscape [download PDF];

and convened three high profile panelists: 

• Omu Anzala, Program Director at the Kenyan Aids Vaccine Initiative, KAVI;
• Peter Godfrey-Faussett, Senior Science Advisor at UNAIDS;
• Robin Shattock, Chair of Mucosal Infection & Immunity at Imperial College;

Moderator Mitchell Warren of AVAC commented: “It is always so valuable to gather diverse global vaccine stakeholders, and to collectively identify the challenges and opportunities that we all face in sustaining scientific, political and financial commitments needed for AIDS vaccine R&D, especially at a time when the science is at its most promising while the financial resources are most constrained.”

Speaking Science to the Public
Co-organizers: AVAC, Global HIV Vaccine Enterprise

This interactive session helped attendees synthesize information into key messages that target audiences can understand, remember and take act upon. IAVI participated in the panel discussion: "The good, the bad, the ugly: Real life experiences with communicating science to reporters and the public," which focused on different perspectives and experiences of communicating science to reporters.

From Bench to Clinic: A Researchers Guide to Move Vaccine Candidates into Trials
Co-organizers: International AIDS Vaccine Initiative, UK HIV Vaccine Consortium, Global HIV Vaccine Enterprise
Taking a candidate vaccine into a Phase I study, even if well characterized in preclinical study, is a complex multi-step process that requires comprehensive knowledge and understanding of a large number of interrelated issues. This satellite brought together experts on regulatory, manufacturing and product development to discuss how the transition can be done smoothly. It also presented a new interactive webtool, From Bench to Clinic, which gives investigators an overview of key steps in this process, describes the relevant expertise required at each step, and provides estimates of the typical timelines and costs, based on three potential types of vaccine products. For more information on the interactive webtool, please click here.

Celebrating Unsung Champions
Photo Exhibit & Reception Co-Hosted by IAVI, HIVACAT and Planeta Salud
A photo exhibit and reception co-hosted by IAVI, the Catalan congress co-host HIVACAT and the Spanish advocacy group Planeta Salud
celebrated The Unsung Champions of AIDS vaccine R&D. From the lab bench to the village square, many of those most vulnerable to HIV infection are making vital contributions to the development of AIDS vaccines. Almost 300 guests attended the reception, which featured photographs by IAVI and Catalan photographer Kim Manresa. “Our work toward a vaccine and an end to AIDS is made possible by this global corps of volunteers, from study participants to community advocates,” said IAVI’s Margie McGlynn.

Click on the title to view the session online.

Emerging Clinical Trial Data
Chairs: M. Esteban, B. Wahren
Speakers: T. Hanke, M. Bakari, R. O'Connell, G. Tomaras, G. Gray, TBD
The First Clinical Evaluation of Conserve-Region Vaccines in Humans
P. Hayes1, J. Vasilyeva2, N. Frahm2, J. Cox1, S. Colloca3, A. Nicosia4, J. Gilmour1, Tomas Hanke5
1IAVI, Imperial College, London, UK; 2FHCRC, Seattle, WA, USA; 3Okairos, Rome, Italy; 4Okairos, CEINGE, Univ of Naples, Naples, Italy; 5Univ of Oxford, Oxford, UK

Oral Abstract Sessions
Click on the title to view sessions online (where available).

Engineering an HIV Envelope Protein to Activate Germline B Cell Receptors of Broadly Neutralizing VRC01-Class Antibodies
Authors: Andrew McGuire1, A.M. Dreyer1, S. Hoot2, A. Lippy1, A. Stuart1, K.W. Cohen1, J. Jardine3, S. Menis3, J.F. Scheid4, A.P. West5, W.R. Schief3, L. Stamatatos1
1Seattle Biomed, Seattle, WA, USA; 2Altravax Inc., Sunnyvale, CA, USA; 3IAVI Neutralizing Antibody CTR  at The Scripps Res Inst, La Jolla, CA, USA; 4The Rockefeller Univ, New York, NY, USA; 5California Inst of Technology, Pasadena, CA, USA

Focusing Antibody Responses to Specific Protein Surfaces Through Site-Selective Glycan Addition
Authors: Torben Schiffner1, K. Leonavicius1, H. Schuster1, L. Kong1, R. Saliba1, F. Wegmann1, P. Huang2, G.B. Stewart-Jones1, W.R. Schief3, B.G. Davis1, Q.J. Sattentau1
1Univ of Oxford, Oxford, UK; 2Univ of Washington, Seattle, WA, USA; 3IAVI Neutralizing Antibody CTR at The Scripps Res Inst,, La Jolla, CA, USA

Impact of TLR9 Stimulation on HIV-1 Env-Specific Immune Responses Elicited in Non-human Primates
Authors: Paola Andrea Martinez Murillo1, C. Sundling1, Y. Feng2, S. O'Dell3, K. Reimann4, J. Mascola3, R. Wyatt2, G.B. Karlsson Hedestam1,
1Karolinska Inst, Stockholm, Sweden;  2IAVI Neutralizing Antibody CTR at The Scripps Res Inst, La Jolla, CA, USA; 3VRC, NIAID, NIH, Bethesda, MD, USA; 4MassBiologics, Univ of Massachusetts Med School, Boston, MA, USA
HIV-1 Fusion Protein (F4/AS01) and Adenovirus-35 Gag-RT-Int-Nef induce potent and durable T-cell and antibody responses in healthy African adults 
Authors: Juliet Mpendo1, G. Omosa-Manyonyi2, E. Ruzagirwa3, W. Kilembe4, F. Roman5, M. Koutsoukos1, A. Lombardo6, L. Dally7, P. Chetty6, P. Bourguignon5, P. Hayes6, J. Gilmour1, J. Cox6, F. Priddy1,
1Uganda Virus Res Inst, Entebbe, Uganda; 2Kenya AIDS Vaccine Initiative, Nairobi, Kenya;  3MRC-Uganda, Entebbe, Uganda;  4Zambia Emory HIV Res Program, Lusaka, Zambia;  5GSK Vaccines, Rixensart, Belgium;  6IAVI, New York, NY, USA;  7Emmes Corp., Rockville, MD, USA

Identifying the minimal mutations in VRC01 required for neutralization potency and breadth to inform vaccine design [Presentation not available]
Authors: Joseph Jardine, Devin Sok, Oleksandr Kalyuzhniy, Michael Kubitz, Yumiko Adachi, Dennis R. Burton, William R. Schief
1The Scripps Res Inst, IAVI, CHAVI-ID, Univ of Washington, La Jolla, CA, USA; 2The Scripps Res Inst, IAVI, CHAVI-ID, La Jolla, CA, USA; 3The Scripps Res Inst, CHAVI-ID, La Jolla,CA, USA; 4The Scripps Res Inst, IAVI, La Jolla,CA, USA

Adjuvants Modify Antibody Effect or Function
Alison Mahan1
1Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA

HIV vaccine design to induce broadly neutralizing antibodies [Presentation not available]
William Schief1
1IAVI Neutralizing Antibody Center and Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, USA

Poster Discussions
Click on the title to view the e-posters online (where available).

Vaccine-Elicited CD4 Binding Site-Directed Antibodies Utilizing the Macaque Equivalent of the Human VH1-2 Heavy Chain Variable Gene Segment
Marjon Navis1, K. Tran2, Y. Li2, G. Phad1, C. Sundling1, R. Wilson2, M. Soldemo1, K. McKee3, J. Mascola3, R.T. Wyatt2, G.B. Karlsson Hedestam1
1Karolinska Inst, Stockholm, Sweden; 2IAVI Neutralizing Antibody Center atThe Scripps Res Inst, La Jolla, CA, USA; 3VRC, NIAID, NIH, Bethesda, MD, USA

Targeting HIV-1 Where It Hurts
Tina Ahmed1, P. Hayes2, N. Borthwick1, B. Ondondo1, E. Hayton1, S. Colloca3, A. Nicosia3, A. McMichael1, J. Gilmour2, L. Dorrell1, T. Hanke1
1Univ of Oxford, Oxford, UK;  2IAVI Human Immunology Laboratory, Chelsea and Westminster Hospital and Imperial College, London, UK;  3Okairòs, Rome, Italy 

Phase I Safety and Immunogenicity of Electroporated HIV DNA with or Without Interleukin 12 in Healthy HIV-Seronegative African Volunteers
Authors: Etienne Karita1, J. Mpendo2, O. Anzala3, J. Nyombayire1, A. Namvumbya2, G. Mutua3, C. Schmidt4, J. Cox5, J. Gilmour5, B. Rasmussen4, J. Lehrman4, J. Eldrige6, M. Egan6, D. Hannaman7, L. Dally8, C. Smith8, S. Allen9, F. Priddy4, P. Fast4
1Projet San Francisco, Kigali, Rwanda; 2UVRI-IAVI HIV Vaccine Programme, Entebbe, Uganda;3KAVI-Kangemi, Univ of Nairobi, Nairobi, Kenya; 4IAVI, New York, NY, USA; 5IAVI Human Immunology Laboratory, London, UK; 6Profectus BioSciences, Inc., Tarrytown, NY, USA; 7ICHOR Med Systems, Inc., San Diego, CA, USA; 8The EMMES Corporation, Rockville, MD, USA; 9Emory Univ, School of Medicine, Atlanta, GA, USA
Getting to Zero with an HIV Vaccine: Modeling the Impact of Introduction of the Current HIV Vaccine Pipeline Under the Investment Framework
Authors: J. Aylward2, E.D. Donaldson1, K. Fisher1, T. Harmon2, M. McGlynn2, Arne Naeveke2, J. Stover3, M. Warren1
1AVAC, New York, NY, USA; 2IAVI, New York, NY, USA; 3Futures Inst, Glastonbury, CT, USA

A Survey of Community Opinions and Preferences on PrEP, Microbicides and Vaccines in 5 Regions and with Key Populations in Kenya
Authors: Judie Mbogua1, B.P. Ngongo1, J. Ndegwa2, B. Bender1, F. Manguyu1
1IAVI, Nairobi, Kenya; 2Kenya AIDS NGO Consortium, Nairobi, Kenya

Poster Presentations by IAVI & Partners 
Click on the number to view the e-posters online (where available).  

Arginine-scanning of PG16 paratope defines quaternary epitope
Authors: Pancera M, Zhu J, O’Dell S, Yang Y, Zhang B, Changela A, McLellan J S, Wu X, Zhou T, Burton D R, Koff W C, Mascola J, Kwong P D

Vaccine-elicited B cell responses against the HIV-1 primary receptor binding site
Wang  Y, Sundling C, Dai  K, Wilson R, O’Dell S, Zhu J, Xiao  Y, Mascola  J.R., Karlsson Hedestam  G.B., Wyatt R.T., Li Y.

ntegration of Prevention, Screening, and Treatment for Common Diseases for Vaccine Trial Target Populations: the Good Health Package
Authors: Dissen E, Kwok C, Munir N, Simpungwe M.K, Ahmed N, Abdallah J, Dinh C, Sharkey T, Tichacek A, Inambao M, Kilembe W, Allen S.

Performance of commercially available HIV rapid and HIV ELISA test kits on samples from a preventative HIV vaccine trial to evaluate vaccine induced seropositivity (VISP)
Authors: Chetty P, Stevens G, Farah B, Mwangi I, Wangui S, Schmidt C, Anzala O

A Mixed-Methods Assessment of Understanding (AoU) Tool for HIV Vaccine Trials: Results From a Comparative Study in South Africa and Uganda’
Authors: Welsh S., Lindegger G., Quayle M., Singh S., Mark D., Wallace M., Bekker L.G., Roux S., Bahemuka U., Ruzagira E., Priddy F., Fast P., Mbogua J., Bahati P., Bender B.

HIV-1 replicative capacity independently predicts CD4+ T-cell decline and may play a role in establishment of early immune activation and memory cell depletion
Authors: Prince J, Claiborne D, Yu T, Tang J, Carlson J, Kilembe W, Mulenga J, Lakhi S, Gilmour J, Price M A, Allen S, Hunter E

Selection and optimisation of a nasal sampling method for application into Phase 1 Clinical Trials at multiple clinical research
Authors: Bergin P, Langat R, Omosa-Manyonyi G, Farah B, Bizimana J, Umvirigihozo G, Nyombayire J, Ouattara G, Ingabire R, Park H, Chetty P, Verlinde C, Laufer D, Cox J, Stevens G, Fast P, Gilmour J, Karita E and Anzala O.

The Role of Technical Assistance in Establishing Couples' Testing as Standard of Care for HIV Vaccine Trial Participants
Authors: Appiagyei A, Mwaanga A, Sinabambenye R, Hoagland A, Gudo E, Banda H, Mulenga M, Mutumwinka B, Ahmed N, Siangonya B, Inambao M, Karita E, Kilembe W, Allen S.

An inactivated viral vaccine that displays conformationally intact HIV-1 clade B envelope trimers induces neutralizing antibodies in rabbits
Authors: Lindsay R, Powell R, Wilson A, Wright K, Yuan M, Kemmelman M, Lopez M, Arendt H, DeStefano J, Carpov A, Domi A, King C R, Parks C

Replicating vesicular stomatitis virus vectors (VSV) expressing membrane-anchored MPER immunogens
Authors: Yuan, M, Kemelman M, Lopez M, Wilson A, Arendt H, Martinez J, Domi A, DeStefano J, King C R, Lindsay R, Parks, C L

Development of broadly neutralizing antibody responses in a large sub-Saharan African HIV primary infection cohort
Authors: Landais E, Simek M, Price, Amornkul P N, Cormier E, Fast P, Gilmour J, Allen S, Karita E, Kilembe W, Lakhi S, Inambao M, Kamali A, Sanders E J, Anzala O, Wrin T, Poignard P, The IAVI African HIV Research Network

Filling in the immunological space: Low seroprevalent Ad HIV vaccines +/- adjuvanted protein or electroporated DNA elicit different immune profiles
Authors: Cox J,  Keefer M,  Ruzagirwa E, Mpendo J, Kilembi W, Chomba E, Omosa-Manyoni G, Baden L, Karita E, Mutua G, Gray G, Bekker L, Churchyard G, Kiwanuka N,  Roman F, Pau M,  Eldridge J, Hannaman D,  McElrath J, Bourguinon P, Anzala O, Priddy F, Laufer D, Schmidt C, Fast P, Gilmour J.

Replicating VSV-SIV chimeric viral vector immunogenicity in Indian rhesus macaques
Authors: Morrow G, Jurgens C, Domi A, Coleman J, Sharma P, Powell R, Ouellette I, DeStefano J, Martinez J, Arendt H, RasmussenB, Richter King C, Parks C

CDV vectors as vaccine candidates
Authors: Morrow G, Zhang J, Domi A, Wallace O, Coleman J, Sharma P, Powell R, Ouellette I, Rasmussen B, Richter King C, Parks C

Testing efficacy of DNA/IL-12 delivered by Electroporation with vector boost in the SIVmac239 system
Authors: Morrow G, Wilson A, Powell R, Ouellette I, Coleman J, Sharma P, Lindsay R, Boggiano C, Rasmussen B, Barouch D, Parks C, King C R

Antibody glycosylation can be transiently altered after vaccination against HIV
Authors: Mahan A, Tedesco J, Dionne K, Chung A, Cox J, Koff A, Barouch D, Michael N, Kim J, Suscovich T, Alter G

Analysis of vaccine-elicited antibodies to the HIV-1 gp120 CD4 binding site reveals distinct modes of Env recognition to guide immunogen re-design
Authors: Tran K;  Poulsen C; Guenaga J, de Val Alda N; Wilson, R; Sundling, C2; Li, Y1,3; Stanfield, R4; Wilson, I1,4,5; Ward A, Karlsson Hedestam G.B, Wyatt, R.T.

Steric access to the HIV-1 co-receptor binding site is manifest on the virus prior to CD4 engagement at the target cell surface
Authors: Chakrabarti B K, Wyatt R T

Mucosal specimen collection, processing and assay - experience from a resource-limited setting in Kenya
Authors: Omosa-Manyonyi G, Farah B, Ouattara G, Anzala O, Mutua G, Ogutu H, Ogola S, Ndambuki R, Mutisya E, Nyange J, Langat R, Bergin P, Laufer D, Gilmour J, Lehrman J, Verlinde C, Chinyenze K, Park H, Fast P

Immunogenicity of homologous and heterologous regimens of Ad26-EnvA.01 and Ad35-EnvA HIV vaccines in HIV-uninfected volunteers in the US and Africa
Authors: Gilmour J,  Baden L, Frahm N, Laufer D, Hayes P, Peter L, Seaman M., Cormier E,  Hural J,  Karita E, Mutua G, Gail-Bekker L, Gray G, Page-Shipp L, Fast P,  Cox J.H, and Barouch D.

Low Rates of ARV Use and Uptake Among Discordant Couples Followed in Government Clinics in Zambia
Authors: Dinh, C, Kwok C, Dissen E, Sharkey T, Munir N, Chadd P, Parris K, Kilembe W, Inambao M, Tichacek A, Allen S.

Host factors, viral replicative capacity, and viral adaptation work in concert to define HIV-1 subtype C disease progression
Authors: Claiborne, Prince J, Yu T, Tang J, Carlson J, Lakhi S, Kilembe W, Gilmour J, Price M A, Allen S, Hunter E

ARV use in HIV-positive pregnant women who attend Couples’ Voluntary Counseling and Testing services in the Copperbelt province, Zambia
Authors: Kwok C, Inambao M, Kilembe W, Simpungwe M.K., Dissen E, Ahmed N, Chadd P, Munir N, Parris K, Abdallah J, Kuo W.-H., Tichacek A,  Allen S.

Safety in a Phase 1 placebo-controlled, double-blind, randomized trial evaluating two adenovirus HIV vaccines in three different geographic regions
Authors: Karita E, Mutua G, Gail-Bekker L, Gray G, Page-Shipp L, Baden L, Stevens G, Grunenberg N, Barouch D, Fast P, Laufer D

The conference website and e-poster portal feature additional resources, including other webcasts and poster presentations.